Bioclones (Pty) Ltd
http://www.bioclones.co.za/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bioclones (Pty) Ltd
Alys Is An Asset Play Wanting Big Pharma Attention
Leaders of a new dermatology-focused biotech, which has launched with 14 development programs in its pipeline, explain the rationale behind the company creation and the ideal exit scenario.
Alys Puts Skin In The Dermatology Game With $100m Launch
Having adopted a similar model to set up Centessa, investment firm Medicxi is merging six of its portfolio companies to create an ambitious immuno-dermatology group.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology
More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.
Company Information
- Industry
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Ribotech (Pty) Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice